Reducing invasive tests for patients with blood in urine

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The SeARCH-trial evaluates the effectiveness of a molecular urine test as a primary diagnostic tool for patients with microscopic hematuria, which can indicate serious conditions like bladder cancer. Currently, most patients undergo invasive procedures such as cystoscopy, despite a low cancer risk of 2-5%. This trial aims to implement a 'urine-first' strategy, where only those with abnormal urine test results will proceed to invasive diagnostics. The study will also assess patient preferences, reported outcomes, and healthcare costs to determine the overall impact on patient quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Microscopically confirmed microscopic hematuria of voided urine defined as ≥3 erythrocytes per high power field
* Male patients ≥40 years
* Female patients ≥50 years

Exclusion Criteria:

* History of urothelial bladder- or urinary tract cancer
* Presence of macroscopic (visible) hematuria
* Woman who is or may be pregnant

Where it's running

• SeARCH-trial Pijpers
  Rotterdam, Netherlands Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hospital admissions for blood in the urine

  This international observational project will look at how hospitals manage adults admitted with blood in the urine to see which approaches lead to shorter stays and better outcomes.

  Recruiting British Urology Researchers in Surgical Training · London · NCT07395037

• Do women over 50 with sudden bladder infection symptoms and visible blood in their urine need full cancer checks?

  This project will see if women 50 and older who have sudden visible blood in their urine with short-term bladder infection symptoms can safely avoid full cancer investigations.

  Recruiting Vastra Gotaland Region · Uddevalla · NCT07037589

• Screening for bladder cancer using urine tests

  This study is testing if regular urine tests every six months can help catch bladder cancer earlier in people over 50 who are at high risk.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT05646485

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Specimen Collection for Validation of a New urine-based bladder cancer test

  This study collects urine and tumor samples from adults being evaluated or treated for urothelial cancer to validate a next‑generation sequencing platform.

  Recruiting Convergent Genomics, Inc. · Oceanside, California and 22 other locations · NCT07673016

• Dual-target Nectin-4 and HER2 CAR-NK therapy for advanced urothelial carcinoma

  This treatment will try dual-target CAR-NK cells that recognize Nectin‑4 and HER2 in adults with relapsed or metastatic urothelial carcinoma after standard therapies.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07492628

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.